Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHays Regulatory News (HAS)

Share Price Information for Hays (HAS)

Share Price is delayed by 15 minutes
Get Live Data
34.24    0.90 (2.70%)
Bid:
33.86
Ask:
35.30
Spread: 1.44 (4.253%)
Market Cap: £547.50m
HAS Live PriceLast checked at - London Stock Exchange

Intraday Hays Share Chart

Board Changes

16 Jan 2025 07:00

RNS Number : 4829T
Hays PLC
16 January 2025
 

16 January 2025

 

HAYS PLC

BOARD CHANGES

Hays plc ("Hays") today announces the appointment of Michael Findlay to its Board as a Non-Executive Director and Chair-designate. He will join the Board on 20 January 2025 and will succeed Andrew Martin as Non-Executive Chair from 1 May 2025. Andrew will retire on 1 May 2025 after nearly 8 years on the Board.

Michael Findlay is currently Non-Executive Chair of London Stock Exchange plc and a Non-Executive Director of International Distribution Services plc and Jarrold & Sons Limited. Michael is also Chair of Morgan Sindall Group plc but announced yesterday that he will be stepping down from the Board on 28 July 2025. Previous roles include co-head of investment banking for UK and Ireland at Bank of America and Senior Independent Director at UK Mail Group plc.

Cheryl Millington, Hays' Senior Independent Director, who led the succession process, said: "I am delighted that Michael will be joining the Hays Board. Michael is a highly accomplished business leader and a proven Non-Executive and Chair. Having spent his executive career in corporate broking and investment banking, Michael has advised many leading UK plcs on a wide range of strategic, financing and governance matters. He also brings a strong understanding of people intensive and service orientated businesses."

"I also want to take this opportunity to thank Andy on behalf of the Board for his exemplary leadership, during a period of significant change for the Group, and wish him all the very best for the future."

Michael said: "I am delighted to be joining Hays and I look forward to working with the Board and the executive team to drive forward the Group's strategy to create significant value for all stakeholders."

Andy Martin commented: "It has been a privilege to serve on the Board of Hays for nearly 8 years. It is a great company and I wish all of the incredible team every success for the future, and wish Michael all the very best as he leads the Board on this next important step of the Hays journey."

This announcement is made in accordance with Listing Rule 6.4.6. There are no further matters to be disclosed under Listing Rule 6.4.8.

 

Enquiries

Hays plc

Rachel FordKean Marden

FGS GlobalGuy Lamming / Anjali Unnikrishnan / Richard Crowley

 

General Counsel & Company Secretary

Head of Investor Relations & ESG

 

+44 (0) 333 010 2682

+44 (0) 333 010 7092hays@fgsglobal.com

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAUVANRVAUAAAR
Date   Source Headline
28th Nov 202412:14 pmRNSDirector/PDMR Shareholding
26th Nov 202411:02 amRNSHolding(s) in Company
20th Nov 20242:27 pmRNSBoard Committee Changes
20th Nov 20242:07 pmRNSResult of AGM
1st Nov 202410:00 amRNSTotal Voting Rights
25th Oct 20242:10 pmRNSDirector/PDMR Shareholding
23rd Oct 20241:49 pmRNSHolding(s) in Company
16th Oct 20242:01 pmRNSHolding(s) in Company
11th Oct 20247:00 amRNSFirst Quarter Trading Statement
10th Oct 20244:44 pmRNSDirector/PDMR Shareholding - Amendment
10th Oct 202412:45 pmRNSDirector/PDMR Shareholding
7th Oct 20243:14 pmRNSDirector/PDMR Shareholding
7th Oct 202412:43 pmRNSAnnual Financial Report
1st Oct 202410:00 amRNSTotal Voting Rights
27th Sep 20242:39 pmRNSDirector/PDMR Shareholding
12th Sep 20243:52 pmRNSDirector/PDMR Shareholding
9th Sep 20242:45 pmRNSDirector/PDMR Shareholding
6th Sep 20242:16 pmRNSDirector/PDMR Shareholding
4th Sep 20244:30 pmRNSDirector/PDMR Shareholding
2nd Sep 202410:27 amRNSTotal Voting Rights
22nd Aug 20247:00 amRNSFinal Results
20th Aug 20245:00 pmRNSCompany Secretary Change
20th Aug 20244:02 pmRNSHolding(s) in Company
1st Aug 202410:15 amRNSBlock listing Interim Review
1st Aug 202410:00 amRNSTotal Voting Rights
11th Jul 20247:00 amRNSFourth Quarter Trading Statement
1st Jul 202410:00 amRNSTotal Voting Rights
6th Jun 20243:43 pmRNSDirector/PDMR Shareholding
3rd Jun 202410:00 amRNSTotal Voting Rights
3rd May 20242:07 pmRNSResponse to Voting Results
1st May 202410:00 amRNSTotal Voting Rights
16th Apr 20247:00 amRNSThird Quarter Trading Statement
12th Apr 202410:06 amRNSDirector/PDMR Shareholding
9th Apr 202410:22 amRNSHolding(s) in Company
8th Apr 20244:00 pmRNSDirector/PDMR Shareholding
2nd Apr 202410:03 amRNSTotal Voting Rights
28th Mar 202412:20 pmRNSDirector/PDMR Shareholding
20th Mar 20242:40 pmRNSDirector/PDMR Shareholding
1st Mar 202410:00 amRNSTotal Voting Rights
22nd Feb 20247:00 amRNSHalf-year Report
20th Feb 20243:15 pmRNSAppointment of Non-Executive Directors
20th Feb 20243:10 pmRNSBoard and Committee Changes
1st Feb 202411:00 amRNSBlock listing Interim Review
1st Feb 202410:00 amRNSTotal Voting Rights
9th Jan 20247:00 amRNSSecond Quarter Trading Statement
2nd Jan 202410:00 amRNSTotal Voting Rights
13th Dec 20237:00 amRNSDirector/PDMR Shareholding
7th Dec 202311:00 amRNSDirector/PDMR Shareholding
1st Dec 20231:00 pmRNSDirector/PDMR Shareholding
1st Dec 202310:00 amRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.